GlassScriptPhysician profile
Brian R Boucher
NPI 1386614154
$5,926.26
in general payments reported to CMS, 2019-2025
56 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $229 · 2021: $193 · 2022: $417 · 2023: $1,120 · 2024: $1,424 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.33 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $618.93 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $589.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $456.45 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Pfizer INC. | $444.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.30 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $268.60 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $261.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $223.93 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $172.93 | 2022-2025 | |
| Abbott Laboratories | $160.22 | 2024-2025 | Freestyle Libre 3, Octrode |
| Lundbeck LLC | $158.66 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $137.65 | 2024-2025 | Voquezna |
| Corium, LLC | $125.79 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $125.49 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $124.38 | 2019-2025 | Camzyos, Eliquis |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $114.58 | 2019-2025 | Lagevrio |
| Exact Sciences Corporation | $101.86 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $88.14 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $86.65 | 2023-2024 | Rexulti |
| Amgen INC. | $85.08 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $83.89 | 2021-2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $68.05 | 2023-2024 | Briviact, Nayzilam |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.79 | 2025 | Caplyta |
| Stryker Corporation | $63.75 | 2024 | Mild Device Kit |
| Inspire Medical Systems, INC. | $61.84 | 2024-2025 | Inspire |
| Ironshore Pharmaceuticals INC. | $61.84 | 2024 | |
| Sanofi-Aventis U.S. LLC | $56.34 | 2023-2025 | |
| Shield Therapeutics INC | $55.45 | 2025 | |
| Bausch Health US, LLC | $52.97 | 2023-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $51.48 | 2019-2025 | Spravato |
| Ibsa Pharma INC. | $48.00 | 2022-2025 | Tirosint, Licart, Flector |
| Xeris Pharmaceuticals, INC. | $47.41 | 2024 | Keveyis |
| Neurocrine Biosciences, INC. | $46.11 | 2024-2025 | Ingrezza |
| Almatica Pharma LLC | $43.48 | 2025 | Loreev Xr |
| Esperion Therapeutics, INC. | $39.43 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.39 | 2023-2025 | Xifaxan |
| Sanofi Pasteur INC. | $31.80 | 2019-2022 | |
| Medtronic, INC. | $30.68 | 2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $27.96 | 2019-2023 | |
| Alkermes, INC. | $23.06 | 2022 | |
| Genentech USA, INC. | $22.55 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.32 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.72 | 2025 | Rebyota |
| Axsome Therapeutics, INC. | $20.25 | 2024 | Auvelity |
| Medicomp INC | $20.12 | 2025 | Telepatch Cardiac Monitor |
| Antares Pharma, INC. | $19.80 | 2025 | Xyosted |
| Linus Health, INC. | $19.32 | 2024 | Core Cognitive Evaluation |
| Amneal Pharmaceuticals LLC | $19.22 | 2025 | Unithroid |
| Boston Scientific Corporation | $18.80 | 2021 | |
| Tolmar, INC. | $18.08 | 2023 | |
| Mirum Pharmaceuticals, INC. | $17.55 | 2023 | |
| Supernus Pharmaceuticals, INC. | $16.55 | 2022 | |
| Eisai INC. | $16.54 | 2024 | |
| Hologic Sales and Service, LLC | $16.28 | 2025 | Thinprep 2000 Processor, Aptima |
| Tris Pharma INC | $14.41 | 2024 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $14.29 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Boucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.